Si-Bone SEC Filings

SI-BONE, Inc. (SIBN) reported insider sales by Michael A. Pisetsky, SVP, Ops & Adm/Chief Legal Officer, on 10/02/2025. The Form 4 shows a total of 3,128 shares of common stock sold across multiple trades to satisfy tax withholding on vesting restricted stock units; these sales are described as a "sell to cover" and not discretionary. Reported weighted average prices per transaction are $14.255, $14.1053, and $14.2537, and the filing lists 256,556, 256,522, and 255,224 shares beneficially owned after each reported sale line. The filing also discloses 132,362 shares issuable on settlement of restricted stock units retained by the reporting person.

SI-BONE, Inc. (SIBN) Chief Financial Officer Anshul Maheshwari reported the sale of a total of 3,311 shares of common stock on 10/02/2025 to satisfy tax withholding tied to vesting restricted stock units. The transactions were executed as two separate sell-to-cover events at weighted-average prices of $14.2237 and $14.1711, respectively, with execution prices within the disclosed ranges.

After these sales, the reporting person beneficially owns 211,134 to 212,691 shares depending on line reporting, which includes 150,203 restricted stock units that remain subject to settlement. The filing indicates the sales were non-discretionary and intended solely to cover tax obligations rather than open-market trading decisions.

SI-BONE, Inc. (SIBN) reported an insider transaction by its President, Commercial Ops, Anthony J. Recupero. On 10/02/2025, he sold 1,557 shares at a weighted average price of $14.2374 and 1,754 shares at a weighted average price of $14.27.

The filing states these were sell-to-cover sales to satisfy tax withholding upon RSU vesting and were not discretionary trades. Following the transactions, he beneficially owned 271,977 shares. This total includes 141,167 shares issuable upon settlement of restricted stock units, with each RSU representing one share.

Anthony J. Recupero, President, Commercial Ops of SI-BONE, Inc. (SIBN), reported routine sales on 08/18/2025 to cover tax withholding arising from vested restricted stock units. The Form 4 shows two disposition entries totaling 3,833 shares sold (2,126 and 1,707 shares) at weighted-average prices of $15.627 and $15.6134, executed in multiple trades within price ranges noted in the footnotes. After the reported transactions, the filing shows 275,288 shares beneficially owned and discloses 147,947 shares issuable upon settlement of outstanding restricted stock units. The filing identifies the sales as "sell to cover" for tax obligations and not discretionary trading.

Michael A. Pisetsky, SVP, Ops & Adm and Chief Legal Officer of SI-BONE, Inc. (SIBN), reported sales on 08/18/2025 that were executed to satisfy tax withholding obligations on vesting restricted stock units through a "sell-to-cover" process. The filing shows two non-derivative dispositions: 1,851 shares sold at a weighted-average price of $15.6524 and 1,478 shares sold at a weighted-average price of $15.6171, with transaction prices ranging from $15.49 to $15.80. After these transactions the reporting person beneficially owned 258,352 shares. The filing discloses that 138,504 of those shares are issuable upon settlement of restricted stock units, each representing a contingent right to one share.

Insider sale to cover taxes: SI-BONE Chief Financial Officer Anshul Maheshwari reported sales of common stock on 08/18/2025 to satisfy tax withholding on vested restricted stock units. The Form 4 shows two sell-to-cover transactions: 1,276 shares sold at a weighted average price of $15.5924 and 2,185 shares sold at a weighted average price of $15.5538, reducing beneficial ownership to 216,630 and 214,445 shares respectively as reported for each line. The report notes 156,983 shares remain issuable upon settlement of outstanding restricted stock units. The filing states these sales were non-discretionary and executed in multiple trades across price ranges disclosed in the footnotes.

SI-BONE insider sale tied to RSU tax withholding: Laura A. Francis, who serves as both Chief Executive Officer and a director, reported multiple dispositions of her common stock to satisfy tax withholding on vested restricted stock units. The transactions on 08/18/2025 consisted of five grouped sales totaling 11,343 shares disposed at weighted-average prices in the roughly $15.52–$15.83 range, producing the reported per-trade weighted averages shown. After these transactions the filing shows Ms. Francis directly beneficially owns 419,704 shares and indirectly owns 362,141 shares through The David & Laura Joint Rev Tr., with 396,297 shares included as shares issuable upon settlement of RSUs.

OrbiMed files Amendment No. 5 to a Schedule 13G/A reporting ownership in SI-BONE, Inc. (SIBN). OrbiMed Capital LLC reports beneficial ownership of 2,184,200 shares, representing 5.1% of SI-BONE's common stock, with sole voting and dispositive power over those shares. OrbiMed Advisors LLC reports beneficial ownership of 394,779 shares, representing 0.9%, with shared voting and dispositive power. Together the reporting persons hold 6.0% of the class on behalf of other persons and exercise investment and voting power through a management committee of three named members. The filing states the shares were acquired in the ordinary course of business and not for the purpose of changing control.

Champlain Investment Partners, LLC reported beneficial ownership of 2,140,074 shares of SI-BONE, Inc. common stock, representing 5.0% of the outstanding class. The filing states Champlain is organized in Vermont and acts as an investment adviser.

The report breaks down voting and dispositive power: 1,368,619 shares are listed as sole voting power and 2,140,074 shares as sole dispositive power. The filer certifies the holdings were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.